Skip to main content

Your search for “Liver Cancer” returned 138 results

Clinical Trial Evaluates Engineered Smallpox Vaccine as Potential Liver Cancer Killer

April 9, 2013

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.

Diabetes Drug Found No Better Than Placebo at Treating NAFLD

May 12, 2016

…some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the…

Immune Cell Identity Crisis: What Makes a Liver Macrophage a Liver Macrophage?

October 3, 2019

UC San Diego researchers investigated how a type of immune cell called a macrophage becomes specialized to the liver. Their study, published October 3, 2019 in Immunity, sets the stage for understanding how macrophage specialization gets disrupted by — or contributes to — liver disease.

A New Strategy for Prevention of Liver Cancer Development

November 14, 2017

Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs. However, an unexpected finding made by a team of University of California…

UC San Diego and Samsara Sciences Team Up to Advance Liver Tissue Models

January 14, 2016

…techniques and methods for the isolation and characterization of liver cells that will help drive new research on liver biology, drug safety and efficacy, and the treatment of liver diseases.

Nanospheres Safely Deliver High Chemotherapy Doses in Response to Tumor Secretions

July 14, 2015

Scientists have designed nanoparticles that release drugs in the presence of a class of proteins that enable cancers to metastasize. That is, they have engineered a drug delivery system so that the very enzymes that make cancers dangerous could instead guide their destruction.

Selective, Toxin-Bearing Antibodies Could Help Treat Liver Fibrosis

July 12, 2021

UC San Diego researchers discovered that immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and cirrhosis, in mouse models of human disease.

A Target for Potential Cancer Drugs May, In Fact, Worsen Disease

November 9, 2021

Researchers reveal a previously unrealized complexity in cancer development, one that raises concerns and caution about targeting an enzyme popular in oncological treatments.

Mutational Signature Linking Bladder Cancer and Tobacco Smoking Found With New AI Tool

September 26, 2022

UC San Diego researchers have for the first time discovered a pattern of DNA mutations that links bladder cancer to tobacco smoking. The work could help identify what environmental factors, such as exposure to tobacco smoke and UV radiation, cause cancer in certain patients.

Preclinical Data Shows Combination Immunotherapy Could Stop Liver Cancer Growth

March 13, 2019

New preclinical data from University of California San Diego School of Medicine and Moores Cancer Center offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.

Category navigation with Social links